Bristol Myers Squibb (BMS) has reported positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel, formerly BMS-986393), an investigational CAR-T therapy targeting GPRC5D in multiple myeloma.
The study met its primary endpoint of overall response rate (ORR) and its key secondary endpoint of complete response rate (CRR) in heavily pretreated patients with relapsed or refractory multiple myeloma. The population had received at least four prior lines of therapy and had been exposed to an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 therapy and a BCMA-directed therapy. The trial also included patients who had previously received CAR-T therapy.
For now, however, BMS has only announced that the prespecified endpoints were met. The company has not yet disclosed the numerical ORR, CRR, duration of response, progression-free survival or detailed safety results from QUINTESSENTIAL. Those data will be important for understanding how strong the result really is.
What level of evidence is this?
QUINTESSENTIAL is an open-label, single-arm Phase 2 study. The trial was designed to evaluate whether arlo-cel could produce a sufficiently strong response in a population with few remaining treatment options, rather than to compare the therapy directly against another drug.
That distinction matters.
A positive result in a single-arm registrational study can provide important evidence of antitumor activity, particularly in heavily pretreated multiple myeloma. But it does not establish that arlo-cel is superior to Talvey, another CAR-T therapy, chemotherapy or other available treatments.
In other words, the trial answers an important question: does arlo-cel have enough activity in this difficult-to-treat population to justify further development and potentially support regulatory review?
It does not yet answer the bigger question: is arlo-cel a better treatment than its competitors?
The complete response endpoint is nevertheless worth watching closely. In multiple myeloma, achieving a response is only part of the story. How deep the response becomes and how long it lasts can be just as important. The numerical CRR and duration of response from QUINTESSENTIAL will therefore provide much more context than the topline announcement alone.
The bigger question: what happens after BCMA?
This may be where arlo-cel becomes particularly interesting.
BCMA has become one of the most important targets in modern multiple myeloma treatment. BCMA-directed CAR-T therapies and bispecific antibodies can produce deep responses, but patients can eventually relapse.
Once a patient progresses after BCMA-directed treatment, treatment becomes considerably more challenging. Resistance may involve changes in antigen expression, disease evolution, T-cell dysfunction and other mechanisms.
GPRC5D provides a different target.
Unlike BCMA, GPRC5D expression can remain available on myeloma cells even after previous BCMA-directed therapy. BMS describes GPRC5D expression as independent of BCMA expression and says it can be maintained after BCMA-directed treatment.
That creates an attractive therapeutic concept: rather than continuing to attack the same target after resistance develops, clinicians may be able to switch the immune system to another antigen.
This is why the inclusion of patients previously treated with BCMA-directed therapies is one of the most important features of QUINTESSENTIAL.
Earlier arlo-cel data already provided a strong signal. In the published Phase 1 study, 79 evaluable patients had an ORR of 87% and a complete response rate of 53%. Median duration of response was 18 months and median progression-free survival was 18.3 months.
Those numbers were encouraging, but the Phase 1 population was not identical to the later registrational population.
The new Phase 2 study is much more directly relevant to the potential post-BCMA setting. If the final data show that arlo-cel can maintain deep and durable responses in patients whose disease has already progressed after BCMA therapy, its clinical significance would be considerably stronger.
If the response rate falls substantially from the earlier study, or if deep responses are concentrated primarily among patients without prior BCMA CAR-T exposure, the interpretation would be more cautious.
The detailed dataset will tell us which scenario is closer to reality.
Arlo-cel vs. Talvey: not simply a head-to-head battle
GPRC5D is already a clinically validated target.
Johnson & Johnson’s Talvey (talquetamab), a GPRC5D×CD3 bispecific antibody, demonstrated that targeting GPRC5D can produce meaningful responses in multiple myeloma.
But arlo-cel and Talvey are very different treatment approaches.
Arlo-cel is an autologous CAR-T therapy. The patient’s T cells are collected, genetically modified and manufactured before being returned after lymphodepleting chemotherapy.
Talvey is an off-the-shelf bispecific antibody that can be administered without the individualized manufacturing process required for CAR-T.
That difference could make the two approaches complementary rather than simple substitutes.
For a patient whose disease is progressing rapidly and who cannot afford to wait for CAR-T manufacturing, an immediately available therapy may be attractive. For a patient who can undergo leukapheresis, manufacturing and lymphodepletion, a one-time CAR-T treatment offering a deep and durable response may have a different appeal.
The key question for arlo-cel is therefore not simply whether its ORR is a few percentage points higher than Talvey’s.
The more important question is whether a single CAR-T infusion can provide a meaningfully longer period of disease control and treatment-free time.
If the efficacy and durability are broadly similar to continuously administered therapy, the complexity of CAR-T manufacturing becomes a significant disadvantage.
If arlo-cel produces substantially deeper or longer-lasting responses, its value proposition becomes much stronger.
Safety will also matter
BMS has said that the safety profile of arlo-cel was consistent with other CAR-T therapies and GPRC5D-targeting therapies in multiple myeloma.
That is reassuring, but it is not the same as demonstrating a safety advantage.
GPRC5D-directed therapies have their own characteristic on-target effects, while CAR-T therapy carries familiar risks such as cytokine release syndrome and neurologic toxicity. The earlier arlo-cel study reported transient grade 1/2 skin, nail and oral adverse events related to on-target/off-tumor activity.
The full QUINTESSENTIAL safety dataset will therefore be important, particularly because the trial population is heavily pretreated and may have limited physiological reserve.
What does this mean for BMS?
Arlo-cel is unlikely to transform BMS’s business overnight.
The initial target population is heavily pretreated multiple myeloma patients, including those who have already received BCMA-directed therapy. This is a clinically important group with substantial unmet need, but it is much smaller than earlier-line multiple myeloma populations.
CAR-T therapy also has practical limitations, including cell collection, manufacturing, lymphodepletion, hospital infrastructure and patient fitness.
But the strategic value of arlo-cel could be greater than its initial commercial opportunity suggests.
BMS already has two important CAR-T franchises: Abecma, targeting BCMA in multiple myeloma, and Breyanzi, targeting CD19 in B-cell malignancies.
If arlo-cel eventually reaches the market, BMS could add a GPRC5D-directed CAR-T to that portfolio, giving the company another target in multiple myeloma.
More importantly, as BCMA-directed treatments move into earlier lines of therapy, the number of patients who eventually relapse after BCMA treatment could increase.
That could create a growing population in which a different target such as GPRC5D becomes clinically relevant.
The real test is still Phase 3
The next major step is QUINTESSENTIAL-2, a randomized Phase 3 study evaluating arlo-cel in patients who have received fewer prior lines of therapy.
BMS’s development plan has been focused on a substantially earlier treatment setting, with arlo-cel being compared with standard regimens. BMS previously projected approximately 440 patients for the study, with progression-free survival and MRD-negative complete response among the primary endpoints and overall survival and ORR among key secondary endpoints.
This is a completely different level of evidence.
The Phase 2 study asks whether arlo-cel has enough activity in a heavily pretreated population to move forward.
The Phase 3 study asks whether it can outperform established treatment strategies in patients who are earlier in their disease course and have more therapeutic options.
That is where the commercial opportunity becomes much larger — but so does the competition.
BCMA CAR-T therapies, BCMA bispecific antibodies and other emerging multiple myeloma combinations are all moving into earlier lines of treatment.
So, the September 2026 QUINTESSENTIAL result is clearly good news for arlo-cel, but it is not the final verdict.
The most interesting part may be what happens after BCMA. If arlo-cel can deliver deep, durable responses in patients whose disease has already escaped BCMA-directed therapy, GPRC5D CAR-T could become an important second-target strategy in multiple myeloma.
For now, though, the numerical efficacy, durability and safety data are still needed.
The Phase 2 result opens the door. The follow-up data — and ultimately Phase 3 — will determine how far arlo-cel can go.
